Tag: nasdaq:avxl

September 8, 2021

10 Top Stem Cell Companies on the NASDAQ

The global stem cell therapy market is expected to experience significant growth over the next few years. Here are the...
October 9, 2019

Anavex Life Sciences Announces Extension of Clinical Study in Alzheimer’s Disease

The company announced the start of the ATTENTION-AD long-term extension study in patients with early Alzheimer's disease.
October 2, 2019

Anavex Life Sciences Issued Patent for Alzheimer’s Disease Treatment

The company received the patent from the USPTO for its lead candidate ANAVEX®2-73 to treat Alzheimer's disease.
June 25, 2019

Anavex Life Sciences Doses First Patient in Extension Study to US Phase 2 Clinical Trial of ANAVEX2-73

Anavex Life Sciences (NASDAQ:AVXL) has announced that the first patient that completed the Phase 2 clinical trial ANAVEX2-73-RS-001 has moved...
June 6, 2019

Anavex Life Sciences Doses First Patient in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome

Anavex Life Sciences (NASDAQ:AVXL) has announced it has dosed its first patient in its AVATAR Phase 2 trial of ANAVEX2-73...
October 19, 2018

Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX2-73

Anavex Life Sciences (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including...
July 9, 2018

Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX2-73 for the Treatment of Parkinson’s Disease Dementia

Anavex Life Sciences (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, today...